Q2 2026 saw revenues rise to $496M, driven by the addition of LUMRYZ and strong LYBALVI sales, but net income dropped sharply due to higher expenses and interest from the Avadel Acquisition. The company completed a $2.3B acquisition, issued $1.5B in new debt, and faces ongoing litigation and contin…
Q2 2026 saw revenues rise to $496M, driven by the addition of LUMRYZ and strong LYBALVI sales, but net income dropped sharply due to higher expenses and interest from the Avadel Acquisition. The company completed a $2.3B acquisition, issued $1.5B in new debt, and faces ongoing litigation and contingent liabilities.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
